RxSight Quarterly Income Statements Chart
Quarterly
|
Annual
RxSight Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sales | 33,637,000 | 37,895,000 | 40,214,000 | 35,314,000 | 34,887,000 | 29,512,000 | 28,580,000 | 22,199,000 | 20,810,000 | 17,489,000 | 16,088,000 | 12,615,000 | 11,360,000 | 8,942,000 | 8,426,000 | 5,786,000 | 4,897,000 |
| cost of sales | 8,447,000 | 9,566,000 | 11,426,000 | 10,094,000 | 10,637,000 | 8,827,000 | 10,926,000 | 8,468,000 | 8,795,000 | 7,123,000 | 8,666,000 | 7,259,000 | 6,572,000 | 5,181,000 | 5,557,000 | 4,445,000 | 5,709,000 |
| gross profit | 25,190,000 | 28,329,000 | 28,788,000 | 25,220,000 | 24,250,000 | 20,685,000 | 17,654,000 | 13,731,000 | 12,015,000 | 10,366,000 | 7,422,000 | 5,356,000 | 4,788,000 | 3,761,000 | 2,869,000 | 1,341,000 | -812,000 |
| yoy | 3.88% | 36.95% | 63.07% | 83.67% | 101.83% | 99.55% | 137.86% | 156.37% | 150.94% | 175.62% | 158.70% | 299.40% | -689.66% | ||||
| qoq | -11.08% | -1.59% | 14.15% | 4.00% | 17.23% | 17.17% | 28.57% | 14.28% | 15.91% | 39.67% | 38.57% | 11.86% | 27.31% | 31.09% | 113.94% | -265.15% | |
| gross margin % | |||||||||||||||||
| operating expenses: | |||||||||||||||||
| selling, general and administrative | 28,976,000 | 28,636,000 | 28,209,000 | 25,608,000 | 24,292,000 | 23,324,000 | 21,165,000 | 19,142,000 | 18,239,000 | 16,255,000 | 15,731,000 | 14,926,000 | 14,388,000 | 13,620,000 | 11,616,000 | 9,076,000 | 6,502,000 |
| research and development | 10,217,000 | 10,367,000 | 9,207,000 | 8,838,000 | 8,291,000 | 8,031,000 | 7,341,000 | 7,101,000 | 7,401,000 | 7,208,000 | 6,681,000 | 6,388,000 | 6,192,000 | 6,719,000 | 5,916,000 | 5,377,000 | 6,563,000 |
| total operating expenses | 39,193,000 | 39,003,000 | 37,416,000 | 34,446,000 | 32,583,000 | 31,355,000 | 28,506,000 | 26,243,000 | 25,640,000 | 23,463,000 | 22,412,000 | 21,314,000 | 20,580,000 | 20,339,000 | 17,532,000 | 14,453,000 | 13,065,000 |
| income from operations | -14,003,000 | -10,674,000 | -8,628,000 | -9,226,000 | -8,333,000 | -10,670,000 | -10,852,000 | -12,512,000 | -13,625,000 | -13,097,000 | -14,990,000 | -15,958,000 | -15,792,000 | -16,578,000 | -14,663,000 | -13,112,000 | -13,877,000 |
| yoy | 68.04% | 0.04% | -20.49% | -26.26% | -38.84% | -18.53% | -27.61% | -21.59% | -13.72% | -21.00% | 2.23% | 21.71% | 13.80% | ||||
| qoq | 31.19% | 23.71% | -6.48% | 10.72% | -21.90% | -1.68% | -13.27% | -8.17% | 4.03% | -12.63% | -6.07% | 1.05% | -4.74% | 13.06% | 11.83% | -5.51% | |
| operating margin % | |||||||||||||||||
| other income, net: | |||||||||||||||||
| interest expense | -5,000 | -6,000 | -5,000 | -5,000 | -6,000 | -6,000 | -4,000 | -230,000 | -1,568,000 | -1,507,000 | -1,451,000 | -1,299,000 | -1,136,000 | -1,060,000 | -1,079,000 | -1,079,000 | -826,000 |
| interest and other income | 2,254,000 | 2,508,000 | 2,707,000 | 2,906,000 | 2,276,000 | 1,585,000 | 1,661,000 | 1,746,000 | 1,777,000 | 1,392,000 | 836,000 | 439,000 | 196,000 | 46,000 | 10,000 | 11,000 | 15,000 |
| income before income taxes | -11,754,000 | -8,172,000 | -5,926,000 | -6,325,000 | -6,063,000 | -9,091,000 | -9,195,000 | -12,403,000 | -13,778,000 | -13,212,000 | -15,605,000 | -16,818,000 | -16,732,000 | -17,592,000 | -15,732,000 | -12,677,000 | -13,474,000 |
| income tax expense | 32,000 | 18,000 | 12,000 | 13,000 | 16,000 | 9,000 | -18,000 | 12,000 | 26,000 | 0 | 4,000 | 2,000 | -4,000 | 3,000 | |||
| net income | -11,786,000 | -8,190,000 | -5,938,000 | -6,338,000 | -6,079,000 | -9,100,000 | -9,177,000 | -12,415,000 | -13,804,000 | -13,212,000 | -15,610,000 | -16,818,000 | -16,732,000 | -17,596,000 | -15,734,000 | -12,673,000 | -13,477,000 |
| yoy | 93.88% | -10.00% | -35.29% | -48.95% | -55.96% | -31.12% | -41.21% | -26.18% | -17.50% | -24.91% | -0.79% | 32.71% | 24.15% | ||||
| qoq | 43.91% | 37.93% | -6.31% | 4.26% | -33.20% | -0.84% | -26.08% | -10.06% | 4.48% | -15.36% | -7.18% | 0.51% | -4.91% | 11.83% | 24.15% | -5.97% | |
| net income margin % | |||||||||||||||||
| other comprehensive loss | |||||||||||||||||
| unrealized loss on short-term investments | -146,000 | -157,000 | -5,000 | -5,000 | |||||||||||||
| foreign currency translation gain | 14,000 | 6,000 | -11,000 | 6,000 | -1,000 | -3,000 | 1,000 | 2,000 | -9,000 | 1,000 | |||||||
| total other comprehensive loss | -132,000 | -151,000 | -85,000 | -9,000 | -8,000 | -3,000 | |||||||||||
| comprehensive loss | -11,918,000 | -8,341,000 | -6,293,000 | -5,699,000 | -6,144,000 | -9,148,000 | -9,122,000 | -12,402,000 | -13,868,000 | -13,126,000 | -15,567,000 | -16,773,000 | -16,817,000 | -17,674,000 | -13,480,000 | ||
| net income per share | |||||||||||||||||
| basic & diluted | -0.29 | -0.2 | -0.14 | -0.16 | -0.16 | -0.25 | -0.25 | -0.35 | -0.4 | -0.42 | |||||||
| weighted-average shares used for eps calculation | |||||||||||||||||
| attributable to common stock, basic & diluted | 40,743,786 | 40,509,646 | 9,591,939.75 | 39,788,621 | 38,455,955 | 36,843,087 | 507,780 | 35,662,397 | 34,498,265 | 31,637,097 | -0.55 | -0.61 | |||||
| loss on extinguishment of term loan | -1,407,000 | -362,000 | |||||||||||||||
| other comprehensive income | |||||||||||||||||
| unrealized gain on short-term investments | -344,000 | 633,000 | -64,000 | -45,000 | 45,000 | 19,000 | -65,000 | 84,000 | -23,750 | 55,000 | -76,000 | -4,000 | |||||
| total other comprehensive income | -355,000 | 639,000 | -65,000 | -48,000 | 55,000 | 13,000 | -64,000 | 86,000 | -29,500 | 45,000 | -78,000 | ||||||
| foreign currency translation | -750 | -6,000 | |||||||||||||||
| change in fair value of warrants | 1,503,000 | 1,214,000 | |||||||||||||||
| expiration of warrant | |||||||||||||||||
| income tax (benefit) expense | 1,000 | ||||||||||||||||
| foreign currency translation loss | 14,000 | -10,000 | -4,000 | -4,000 | -3,000 | ||||||||||||
| attributable to series g common stock, basic and diluted | -0.32 | ||||||||||||||||
| attributable to common stock, basic | -0.61 | 0.09 | -0.68 | -3.28 | |||||||||||||
| attributable to common stock, diluted | -0.61 | 0.09 | -0.68 | -3.53 | |||||||||||||
| unrealized income on short-term investments | -74,000 | ||||||||||||||||
| attributable to common stock, basic and diluted | -0.64 | ||||||||||||||||
| accretion to redemption value of redeemable preferred stock and redeemable stock options | |||||||||||||||||
| earnings allocated to redeemable preferred stock | |||||||||||||||||
| net income attributable to common stockholders | -15,734,000 | -12,673,000 | -13,477,000 | ||||||||||||||
| comprehensive income | -8,240,500 | -12,681,000 | |||||||||||||||
| attributable to redeemable common stock, basic | |||||||||||||||||
| attributable to redeemable common stock, diluted | |||||||||||||||||
| attributable to redeemable common stock, basic and diluted |
We provide you with 20 years income statements for RxSight stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RxSight stock. Explore the full financial landscape of RxSight stock with our expertly curated income statements.
The information provided in this report about RxSight stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.